跳至主要内容
临床试验/NCT00950690
NCT00950690已完成不适用

Observational Study Assessing The Efficacy And Tolerability Of Xalatan™ In Patients With Open Angle Glaucoma And /Or Ocular Hypertension.

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1 个研究点 分布在 1 个国家目标入组 1,289 人开始时间: 2005年7月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,289
试验地点
1
主要终点
Intraocular Pressure

研究概览

简要总结

Efficacy data was not collected or analyzed. This study did assess safety and tolerability of Xalatan.

详细描述

  • Efficacy data not collected or analyzed
  • Safety and tolerability of Xalatan assessed NA

研究设计

研究类型
Observational
观察模型
Other
时间视角
Prospective

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Patient with ocular hypertension at least 22mg Hg
  • •Patient must be over 18 years old

排除标准

  • •None listed in the protocol

研究组 & 干预措施

Study Drug - Xalatan 0.005% eye drops

干预措施: Xalatan 0.005% eye drops (Drug)

结局指标

主要结局

Intraocular Pressure

时间窗: Screening, 10 days, 4 weeks and 12 weeks after beginning treatment

Intraocular pressure was measured at each visit

Humphrey Perimetry Visual Field

时间窗: Visits 1 and 4

Analysis of visual field deficits for abnormalities.

次要结局

未报告次要终点

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验